On November 20, 2013, the Food & Drug Administration (FDA) issued a warning to healthcare professionals of a rare, but serious, risk of a heart attack and death with the use of the cardiac nuclear stress test agents, Lexiscan (Regadenoson) and Adenoscan (Adenosine). The FDA has informed healthcare professionals that they should avoid using these drugs in patients with signs or symptoms of unstable angina or cardiovascular instability, as these patients may be at a greater risk for serious cardiovascular adverse reactions.
These drugs are used for cardiac patients who undergo Radionuclide or Myocardial Profusion Imaging for patients who are unable to undergo adequate exercise stress tests.
The manufacturer of Lexiscan and Adenoscan is Astellas Pharma US, Inc.
If you or a family member have suffered in an injury or unfortunate death with the use of these cardiac nuclear stress test agents prior to November 20, 2013, contact the law firm of Patberg Law Firm at 1-800-4770-6880 or visit our website at www.pcglawfirm.com for more information.